The knee is the largest and strongest joint in your body. When it gets worse, it causes mobility problems and pain.
>> Read More Trend News
More than 1
University of Maryland School of Medicine researchers, however, may have found a way to alleviate the deterioration.
549 volunteers randomly selected from their study took injections of either 30 micrograms of sprifermin, recombinant human fibroblast growth factor 18; 100 micrograms of Sprifermin; or a placebo.
MRI revealed that the group receiving the 100 microgram dose once or twice a year had a slight increase in articular cartilage thickness even after two years. The lower dose group showed lower gains. The placebo group lost cartilage during the same period.
None of the study participants, however, found a significant improvement in their osteoarthritis symptoms.
When the researchers returned and analyzed a small group of participants – osteoarthritis patients with severe pain and narrow gonads in the knee who were at greater risk for disease progression – who received 100 micrograms of sprifermin every six months – showed 18 Months after her last shot a significant improvement in her symptoms.
"These findings support the further investigation of sprifermin as a potential arthritis treatment for both structural modification and symptom relief in higher-risk patients," said Marc Hochberg, senior researcher and professor of medicine at UMSOM.
was published Tuesday in the Journal of the American Medical Association.
© 2019 Cox Media Group.